Foscarnet: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== |
==Background== |
||
*Inhibits DNA polymerase in [[human herpesviruses]] |
*Inhibits DNA polymerase in [[human herpesviruses]] |
||
*Indications: {{#ask: [[Is treated by::foscarnet]] | default=none}} |
*Indications: {{#ask: [[Is treated by::foscarnet]] | default=none}} |
||
=== |
===Spectrum of Activity=== |
||
* |
*Active against all [[human herpesviruses]] |
||
=== Pharmacokinetics and Pharmacodynamics === |
|||
* CSF penetration 66% of serum levels |
|||
== Dosing == |
|||
=== Pediatric Dosing === |
|||
* Induction: foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h |
|||
* Maintenance: foscarnet 90 to 120 mg/kg IV q24h |
|||
== Safety == |
|||
* Nephrotoxic |
|||
* Causes electrolyte abnormalities, including [[hypocalcemia]], [[hypophosphatemia]], [[hyperphosphatemia]], [[hypomagnesemia]], and [[hypokalemia]] |
|||
[[Category:Antivirals]] |
[[Category:Antivirals]] |
||
Revision as of 01:20, 12 September 2020
Background
- Inhibits DNA polymerase in human herpesviruses
- Indications: CMV after hematopoietic stem cell transplantation, CMV after solid organ transplantation, Cytomegalovirus, Herpes simplex virus, Herpesviridae, Post-transplant acute limbic encephalitis
Spectrum of Activity
- Active against all human herpesviruses
Pharmacokinetics and Pharmacodynamics
- CSF penetration 66% of serum levels
Dosing
Pediatric Dosing
- Induction: foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h
- Maintenance: foscarnet 90 to 120 mg/kg IV q24h
Safety
- Nephrotoxic
- Causes electrolyte abnormalities, including hypocalcemia, hypophosphatemia, hyperphosphatemia, hypomagnesemia, and hypokalemia
References
- ^ Dushyantha T. Jayaweera. Minimising the Dosage-Limiting Toxicities of Foscarnet Induction Therapy. Drug Safety. 1997;16(4):258-266. doi:10.2165/00002018-199716040-00003.
